ECNP 2015 Neuropharmacology Award

Faster antidepressants in future? The answer’s yes!

The 2015 ECNP Neuropharmacology Award (Basic Science) was given to Professor Francesc Artigas, Instituto de Investigaciones Biomédicas de Barcelona, Spain in recognition of his outstanding work in the field of systems neuropharmacology. Following the formal presentation of the award by ECNP President Guy Goodwin, Professor Artigas gave a lecture entitled ‘Can we improve speed and efficacy of antidepressant treatments?’

In the future it appears highly likely that the speed and efficacy of antidepressant therapies will be improved

The short answer to this question is “yes!” And three lines of investigation are currently being researched by Professor Artigas and his group.

Faster, faster, faster...

Unlike classic antidepressant therapies, rapidly-acting therapies such as ketamine, PCP and DBS act by modulating the function of glutaminergic neurons. By further understanding the mechanism of action of these therapies, this will aid in the development of more rapidly-delivered antidepressants possibly targeted to this system.

Continued basic and clinical research on the classical, monoamine-based antidepressants is also being carried forward apace by various teams to generate faster acting antidepressant agents within this class. The serotonin receptor (SERT) is the target of most antidepressants. By using small interfering RNAs (siRNA) linked to a selective 5HT reuptake blocker to knock down SERT expression, at least in animal models, rapid antidepressant effects have been noted.

Intranasal delivery – not to be sniffed at!

Professor Artigas’s group is also investigating the delivery and targeting of such customised siRNA molecules to the brain via the intranasal route of administration. The nasal epithelium permits the entry of drugs into the CNS via the olfactory and trigeminal pathways, thereby overcoming the limitations sometimes imposed on drug delivery by the blood brain barrier.

Thus, in the future it appears highly likely that the speed and efficacy of antidepressant therapies will be improved. By administering effective therapies sooner to patients at the outset of depression, it is exciting to speculate that chronicity may be avoided.

 

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Le informazioni contenute nel nuovo sito prescelto possono non essere conformi al D.Ivo 219/06 che regola la pubblicità dei medicinali per uso umano e le opinioni espresse non riflettono necessariamente le posizioni dell’azienda, non sono da essa avvallate.
Accesso riservato a Operatori Sanitari
Per accedere si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi
L’accesso a Progress in Mind Italia è consentito unicamente agli Operatori Sanitari (medici e farmacisti). I contenuti di questo sito sono prodotti da un team di Operatori Sanitari il cui obiettivo è presentare le ultime novità in ambito psichiatrico e neurologico, attraverso interviste, registrazioni audio/video di seminari con opinion leader, report e sintesi di congressi sia internazionali che nazionali. Per poter accedere al sito è quindi necessario registrarsi e fornire alcuni dati così da poter verificare che l‘utente sia un Operatore Sanitario.
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country